Some of the stocks that may grab investor focus today are:
- Wall Street expects Red Hat, Inc. (NYSE:RHT) to post quarterly earnings at $0.81 per share on revenue of $761.60 million after the closing bell. Red Hat shares fell 2.07 percent to close at $147.90 on Friday.
- JD Sports Fashion announced plans to acquire Finish Line Inc (NASDAQ:FINL) for $13.50 per share in cash. Finish Line shares climbed 25.59 percent to $13.25 in pre-market trading.
- Analysts are expecting Paychex, Inc. (NASDAQ:PAYX) to have earned $0.62 per share on revenue of $854.50 million in the latest quarter. Paychex will release earnings before the markets open. Paychex shares declined 2.77 percent to close at $61.73 on Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- argenx SE (NASDAQ:ARGX) reported the orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe. argenx shares rose 0.01 percent to close at79.72 on Friday.
- Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) disclosed that it has achieved both co-primary regulatory endpoints in its two pivotal Phase 3 trials of rimegepant for the acute treatment of migraine. Biohaven Pharmaceutical shares fell 1.05 percent to $24.50 in pre-market trading.